Metagenomi (MGX) Competitors $2.18 -0.03 (-1.36%) Closing price 04:00 PM EasternExtended Trading$2.11 -0.07 (-3.03%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. MRNA, CRDF, FENC, VOR, INBX, CGC, LIMN, ESPR, BTMD, and NBTXShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Moderna (MRNA), Cardiff Oncology (CRDF), Adherex Technologies (FENC), Vor Biopharma (VOR), Inhibrx Biosciences (INBX), Canopy Growth (CGC), Liminatus Pharma (LIMN), Esperion Therapeutics (ESPR), biote (BTMD), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Its Competitors Moderna Cardiff Oncology Adherex Technologies Vor Biopharma Inhibrx Biosciences Canopy Growth Liminatus Pharma Esperion Therapeutics biote Nanobiotix Moderna (NASDAQ:MRNA) and Metagenomi (NASDAQ:MGX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings. Do insiders and institutionals hold more shares of MRNA or MGX? 75.3% of Moderna shares are held by institutional investors. 11.0% of Moderna shares are held by company insiders. Comparatively, 17.8% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, MRNA or MGX? Moderna has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, Metagenomi has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500. Do analysts prefer MRNA or MGX? Moderna currently has a consensus target price of $46.61, suggesting a potential upside of 38.56%. Metagenomi has a consensus target price of $13.00, suggesting a potential upside of 496.33%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 15 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04Metagenomi 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer MRNA or MGX? In the previous week, Moderna had 22 more articles in the media than Metagenomi. MarketBeat recorded 24 mentions for Moderna and 2 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.94 beat Moderna's score of 0.73 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 11 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, MRNA or MGX? Metagenomi has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B4.02-$3.56B-$8.73-3.85Metagenomi$52.29M1.56-$78.06M-$2.11-1.03 Is MRNA or MGX more profitable? Moderna has a net margin of -105.67% compared to Metagenomi's net margin of -172.21%. Moderna's return on equity of -28.69% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-105.67% -28.69% -21.94% Metagenomi -172.21%-31.21%-22.21% SummaryModerna beats Metagenomi on 9 of the 17 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.61M$2.45B$5.61B$9.11BDividend YieldN/A1.79%5.24%4.01%P/E Ratio-1.039.4227.9620.25Price / Sales1.56729.02430.8999.65Price / CashN/A165.3637.4658.16Price / Book0.354.608.045.49Net Income-$78.06M$31.26M$3.18B$250.27M7 Day Performance31.80%4.80%3.72%4.78%1 Month Performance46.31%4.19%3.72%7.20%1 Year Performance-53.02%-2.89%29.92%17.27% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi2.752 of 5 stars$2.18-1.4%$13.00+496.3%-49.2%$82.61M$52.29M-1.03236News CoverageMRNAModerna4.3085 of 5 stars$29.90-1.9%$46.61+55.9%-70.8%$11.79B$3.24B-3.425,800Trending NewsCRDFCardiff Oncology1.4529 of 5 stars$3.65-0.3%$9.88+170.5%+88.2%$243.49M$680K-3.9720Analyst ForecastFENCAdherex Technologies2.2528 of 5 stars$8.47-3.8%$13.00+53.5%+50.7%$242.88M$47.54M-16.6110VORVor BiopharmaN/A$2.67+39.8%N/AN/A$238.67MN/A0.00140INBXInhibrx Biosciences2.5645 of 5 stars$18.35+12.4%N/A+61.8%$236.39M$200K0.16166News CoverageHigh Trading VolumeCGCCanopy Growth0.4216 of 5 stars$1.20-6.3%$2.00+66.7%-81.2%$235.35M$225.65M-0.303,150LIMNLiminatus PharmaN/A$6.93-23.2%N/AN/A$234.65MN/A0.00N/APositive NewsGap DownESPREsperion Therapeutics4.036 of 5 stars$1.11-5.1%$7.00+530.6%-47.5%$231.89M$332.31M-1.39200News CoverageAnalyst RevisionBTMDbiote3.3683 of 5 stars$3.99-5.5%$8.00+100.5%-46.0%$230.88M$197.19M6.54194Positive NewsNBTXNanobiotix2.8029 of 5 stars$4.75-2.5%$8.00+68.6%-0.8%$229.54M$39.18M0.00100 Related Companies and Tools Related Companies Moderna Competitors Cardiff Oncology Competitors Adherex Technologies Competitors Vor Biopharma Competitors Inhibrx Biosciences Competitors Canopy Growth Competitors Liminatus Pharma Competitors Esperion Therapeutics Competitors biote Competitors Nanobiotix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGX Stock Alerts